F186-0295 Screening compound: 4-chloro-N-[4-({[(2,6-difluorophenyl)methyl]carbamoyl}methyl)-1,3-thiazol-2-yl]benzamide

F186-0295 Screening compound: 4-chloro-N-[4-({[(2,6-difluorophenyl)methyl]carbamoyl}methyl)-1,3-thiazol-2-yl]benzamide
F186-0295 Screening compound: 4-chloro-N-[4-({[(2,6-difluorophenyl)methyl]carbamoyl}methyl)-1,3-thiazol-2-yl]benzamide alternative view

Chemical Structure Depiction of ChemDiv screening compound F186-0295
4-chloro-N-[4-({[(2,6-difluorophenyl)methyl]carbamoyl}methyl)-1,3-thiazol-2-yl]benzamide

Available from 1 mg

Formats:

  • Glass Vials (4ml Glass Vials VWR #97047-678)
  • 96-tube racks (Matrix #4247 96-well 1.4ml sealed with capmats, empty cols 1 & 12, 100uL of 10mM)

Shiptime: 1 week worldwide delivery in most cases

Compound Identifiers

ChemDiv Compound ID

F186-0295

Molecular Formula

C19H14ClF2N3O2S (C19 H14 ClF2 N3 O2 S)

Compound Name

4-chloro-N-[4-({[(2,6-difluorophenyl)methyl]carbamoyl}methyl)-1,3-thiazol-2-yl]benzamide

IUPAC name

4-chloro-N-[4-({[(26-difluorophenyl)methyl]carbamoyl}methyl)-13-thiazol-2-yl]benzamide

SMILES

O=C(Cc1csc(NC(c(cc2)ccc2Cl)=O)n1)NCc(c(F)ccc1)c1F

InChI

InChI=1S/C19H14ClF2N3O2S/c20-12-6-4-11(5-7-12)18(27)25-19-24-13(10-28-19)8-17(26)23-9-14-15(21)2-1-3-16(14)22/h1-7,10H,8-9H2,(H,23,26)(H,24,25,27)

InChI Key

GIUFDSLJCMDUNE-UHFFFAOYSA-N

MDL Number (MFCD)

MFCD09009412

Chemical and Physical Properties

Saltdata

n/a

Molecular Weight

421.85

Hydrogen Bond Acceptors Count

5.00

Hydrogen Bond Donors Count

2.00

Rotatable Bond Count

8.00

Number of Nitrogen and Oxygen Atoms

5

Partition Coefficient, logP

4.362

Distribution Coefficient, logD

3.971

Water Solubility, LogSw

-4.80

Polar Surface Area

58.071

Acid Dissociation Constant (pKa)

7.23

Base Dissociation Constant (pKb)

-1.30

Number of Chiral Centers

0.00

Percent sp3 carbon bonding

10.50

F186-0295 in Drug Discovery

Included in Screening Libraries

Allosteric Kinases Inhibitors Library (23117 compounds)

300k Representative Compounds Library (Bemis-Murcko Clustering Algorithm) (286253 compounds)

KRAS-Targeted Library (16000 compounds)

Protein-Protein Interaction Library (218420 compounds)

Chemokine Receptor-Targeted Library (18382 compounds)

Type II Kinase Inhibitors Library (6956 compounds)

Included in 1.7M Stock Database

Therapeutical areas:
  • Cancer
  • Female
  • Congenital
  • Skin
  • Cancer
  • Digestive system
  • Respiratory tract
  • Otorhinolaryngologic
  • Immune system
  • Digestive system
  • Hemic and lymphatic
  • Endocrine
Targets:
  • Kinases
  • Kinases
  • Kinases
Mechanism of action:
  • PPI modulators
  • Receptor's ligands

References: we are preparing a list of scientific research reports with F186-0295 chemical compound. It will be published here after verification.

Frequently Asked Questions

How to purchase chemical compound F186-0295?
Check Price and Availability of F186-0295, then you can add required amount to the Shopping Cart. In the Shopping Cart you can again refine your selection. Once you are sure that it’s exactly what you want you can move forward with the Checkout (to pay online by credit card, or via PayPal), or Request a Quote.
What is the minimum amount of F186-0295 you sell to drug discovery company or institution?
Available from 1 mg in Glass Vials or 96-tube racks.
Delivery options for F186-0295
ChemDiv sends parcels with Express services (UPS, WC).
  • 1–2 days for small orders
  • 2–4 weeks for large selections
Delivery formats for F186-0295
  • 0.5–50 mg of dry powder sample in single glass vials, custom vials
  • DMSO solutions frozen 10μl–250μl@10mM (96 and 384 format)

Custom synthesis of F186-0295 available by request